Thr110

Site Information
HVGNssPtstsPSRY SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3245495

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , phosphopeptide mapping ( 1 ) , western blotting ( 1 )
Disease tissue studied:	bone cancer ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 1 ) , HCT116 (intestinal) ( 1 ) , HeLa (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 , 3 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Treatments:	PF3644022 ( 1 ) , SB203580 ( 1 ) , UV ( 1 )

References
1	Blasius M, et al. (2014) A quantitative 14-3-3 interaction screen connects the nuclear exosome targeting complex to the DNA damage response. Genes Dev 28, 1977-82 25189701 Curated Info
2	Mulhern D (2011) CST Curation Set: 12712; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Curated Info
3	Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Curated Info